Alteration of the Function of the UDP-Glucuronosyltransferase 1A Subfamily by Cytochrome P450 3A4: Different Susceptibility for UGT Isoforms and UGT1A1/7 Variants

被引:30
|
作者
Ishii, Yuji [1 ]
Koba, Hiroki [1 ]
Kinoshita, Kousuke [1 ]
Oizaki, Toshiya [1 ]
Iwamoto, Yuki [1 ]
Takeda, Shuso [1 ]
Miyauchi, Yuu [1 ]
Nishimura, Yoshio [1 ]
Egoshi, Natsuki [1 ]
Taura, Futoshi [2 ]
Morimoto, Satoshi [2 ]
Ikushiro, Shin'ichi [3 ]
Nagata, Kiyoshi [4 ]
Yamazoe, Yasushi [5 ]
Mackenzie, Peter I. [6 ,7 ]
Yamada, Hideyuki [1 ]
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Lab Mol Life Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Pharmaceut Sci, Lab Med Resource Regulat, Fukuoka 8128582, Japan
[3] Toyama Prefectural Univ, Fac Engn, Biotechnol Res Ctr, Imizu, Toyama, Japan
[4] Tohoku Pharmaceut Univ, Sendai, Miyagi, Japan
[5] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan
[6] Flinders Med Ctr, Dept Clin Pharmacol, Adelaide, SA, Australia
[7] Flinders Univ S Australia, Adelaide, SA 5001, Australia
关键词
DRUG-METABOLIZING-ENZYMES; 7-ETHYL-10-HYDROXYCAMPTOTHECIN SN-38; ENDOPLASMIC-RETICULUM; NOMENCLATURE UPDATE; COLORECTAL-CANCER; ACTIVE METABOLITE; GENE SUPERFAMILY; POLYMORPHISMS; GLUCURONIDATION; IRINOTECAN;
D O I
10.1124/dmd.113.054833
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functional protein-protein interactions between UDP-glucuronosyltransferase (UGT)1A isoforms and cytochrome P450 (CYP)3A4 were studied. To this end, UGT1A-catalyzed glucuronidation was assayed in Sf-9 cells that simultaneously expressed UGT and CYP3A4. In the kinetics of UGT1A6-catalyzed glucuronidation of serotonin, both Michaelis constant (K-m) and maximal velocity (V-max) were increased by CYP3A4. When CYP3A4 was coexpressed with either UGT1A1 or 1A7, the V-max for the glucuronidation of the irinotecan metabolite (SN-38) was significantly increased. S-50 and K-m both which are the substrate concentration giving 0.5 V-max were little affected by simultaneous expression of CYP3A4. This study also examined the catalytic properties of the allelic variants of UGT1A1 and 1A7 and their effects on the interaction with CYP3A4. Although the UGT1A1-catalyzing activity of 4-methylumbelliferone glucuronidation was reduced in its variant, UGT1A1(star)6, the coexpression of CYP3A4 restored the impaired function to a level comparable with the wild type. Similarly, simultaneous expression of CYP3A4 increased the Vmax of UGT1A7(star)1 (wild type) and (star)2 (N129K and R131K), whereas the same was not observed in UGT1A7(star)3 (N129K, R131K, and W208R). In the kinetics involving different concentrations of UDPglucuronic acid (UDP-GlcUA), the Km for UDP-GlcUA was significantly higher for UGT1A7(star)2 and (star)3 than (star)1. The Km of UGT1A7(star)1 and (star)3 was increased by CYP3A4, whereas (star)2 did not exhibit any such change. These results suggest that (1) CYP3A4 changes the catalytic function of the UGT1A subfamily in a UGT isoformspecific manner and (2) nonsynonymous mutations in UGT1A7(star)3 reduce not only the ability of UGT to use UDP-GlcUA but also CYP3A4-mediated enhancement of catalytic activity, whereas CYP3A4 is able to restore the UGT1A1(star)6 function.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 50 条
  • [1] Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4
    Fremont, JJ
    Wang, RW
    King, CD
    MOLECULAR PHARMACOLOGY, 2005, 67 (01) : 260 - 262
  • [2] UDP-Glucuronosyltransferase (UGT)-mediated attenuations of cytochrome P450 3A4 activity: UGT isoform-dependent mechanism of suppression
    Miyauchi, Yuu
    Tanaka, Yoshitaka
    Nagata, Kiyoshi
    Yamazoe, Yasushi
    Mackenzie, Peter, I
    Yamada, Hideyuki
    Ishii, Yuji
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (05) : 1077 - 1089
  • [3] Protein-protein interaction of cytochrome P450 and UDP-glucuronosyltransferase: alteration of P450 activity by UGT
    Ishii, Yuji
    Miyauchi, Yuu
    Yamada, Hideyuki
    DRUG METABOLISM REVIEWS, 2011, 43 : 21 - 21
  • [4] Modulation of UDP-glucuronosyltransferase function by cytochrome P450: Evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4
    Takeda, S
    Ishii, Y
    Iwanaga, M
    Mackenzie, PI
    Nagata, K
    Yamazoe, Y
    Oguri, K
    Yamada, H
    MOLECULAR PHARMACOLOGY, 2005, 67 (03) : 665 - 672
  • [5] SUPPRESSION OF CYTOCHROME P450 3A4 ACTIVITY BY UDP-GLUCURONOSYLTRANSFERASE (UGT) 2B7: THE ROLE OF CHARGED RESIDUE(S) IN THE CYTOSOLIC TAIL OF UGT2B7
    Miyauchi, Yuu
    Ishii, Yuji
    Nagata, Kiyoshi
    Yamazoe, Yasushi
    Mackenzie, Peter I.
    Yamada, Hideyuki
    DRUG METABOLISM REVIEWS, 2015, 47 : 34 - 34
  • [6] Characterization of rabbit UDP-glucuronosyltransferase UGT1A7: Tertiary amine glucuronidation is catalyzed by UGT1A7 and UGT1A4
    Bruck, M
    Li, Q
    Lamb, JG
    Tukey, RH
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 344 (02) : 357 - 364
  • [7] Rapid analysis of UDP-glucuronosyltransferase polymorphisms (UGT1A1*28, UGT1A6*2 and UGT1A7*3) using real-time PCR
    Möhrle, B
    Köhle, C
    Bock, KW
    Schwab, M
    Wernet, D
    Münzel, PA
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R160 - R160
  • [8] Monospecific antipeptide antibodies against human hepatic UDP-Glucuronosyltransferase]A subfamily (UGT1A) Isoforms
    Ikushiro, Shin-Ichi
    Emi, Yoshikazu
    Kato, Yoshihisa
    Yamada, Shizuo
    Sakaki, Toshiyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (01) : 70 - 74
  • [9] Telmisartan non-selectively inhibits UDP-glucuronosyltransferase (UGT) 1A and UGT2B proteins 3
    Knights, Kathleen M.
    Spencer, Shane M.
    Miners, John O.
    DRUG METABOLISM REVIEWS, 2011, 43 : 56 - 56
  • [10] IN VITRO EVALUATION OF UDP-GLUCURONOSYLTRANSFERASE (UGT) 1A3 AND UGT2B4 INHIBITION
    Lapham, Kimberly
    Ferguson, Nicholas
    Novak, Jonathan
    Niosi, Mark
    Goosen, Theunis
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S52 - S53